留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《中国老年2型糖尿病防治临床指南(2022年版)》解读

赵维纲

赵维纲. 《中国老年2型糖尿病防治临床指南(2022年版)》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0199
引用本文: 赵维纲. 《中国老年2型糖尿病防治临床指南(2022年版)》解读[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2022-0199
ZHAO Weigang. Interpretation on clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0199
Citation: ZHAO Weigang. Interpretation on clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2022-0199

《中国老年2型糖尿病防治临床指南(2022年版)》解读

doi: 10.12290/xhyxzz.2022-0199
详细信息
    通讯作者:

    赵维纲,E-mail:xiehezhaoweigang@163.com

  • 中图分类号: R587.1

Interpretation on clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China

  • 摘要: 根据我国第七次人口普查数据,2020年我国老年(≥60岁)人口占全国总人口的18.7%,其中约30%(7813万)的老年人患有糖尿病,且95%以上为2型糖尿病。目前我国老年2型糖尿病的防治现状不佳,且存在弱化和消极趋势,其所带来的并发症成为危害老年人健康的主要原因。《中国老年2型糖尿病防治临床指南(2022年版)》汇总了国内外老年糖尿病相关研究信息,为优化我国老年糖尿病防治理念、促进临床诊疗规范化、提高老年糖尿病总体管理水平提供了循证医学证据。本文对其重要内容进行解读,以期更好地指导临床实践。
  • [1] 中国老年2型糖尿病防治临床指南编写组.中国老年2型糖尿病防治临床指南(2022年版)[J].中国糖尿病杂志,2022,30:2-51.
    [2] Li Y, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study[J]. BMJ,2020,369:m997.
    [3] Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group[J]. Diabetes Care, 1997, 20:1664-1669.
    [4] Yang W, Lu J, Weng J, et a1. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010,362:1090-1101.
    [5] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310:948-959.
    [6] Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabete and Prediabetes in China in 2013[J]. JAMA,2017,317:2515-2523.
    [7] 国家统计局(2021-05-11)第七次全国人口普查公报(第五号)[EB/OL]. (2021-05-11)[2022-04-11].http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
    [8] Yan ST, Li CX, Li CL, et al. Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics[J]. Genet Mol Res, 2015,14:3062-3070.
    [9] Tinsley LJ, Kupelian V, D'Eon SA, et al. Association of Glycemic Control With Reduced Risk for LargeVessel Disease After More Than 50 Years of Type 1 Diabetes[J]. J Clin Endocrinol Metab, 2017,102:3704-3711.
    [10] Thompson TJ, Engelgau MM, Hegazy M,et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults[J]. Diabet Med,1996,13:337-340.
    [11] Hou JN, Bi YF, Xu M, et al. The change points of HbA(1C) for detection of retinopathy in Chinese type 2 diabetic patients[J]. Diabetes Res Clin Pract,2011,91:401-405.
    [12] Lindström J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13 years:long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS)[J]. Diabetologia, 2013,56:284-293.
    [13] Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus:a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance[J]. Lancet, 2009,373:1607-1614.
    [14] Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008,358:580-591.
    [15] Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria:21 years follow-up on the Steno-2 randomised trial[J]. Diabetologia, 2016,59:2298-2307.
    [16] ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2008, 358:2560-2572.
    [17] Gerstein HC, Riddle MC, Kendall DM,et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J]. Am J Cardiol, 2007,99:34i-43i.
    [18] van Hateren KJ, Landman GW, Kleefstra N, et al. Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20)[J]. Int J Clin Pract, 2011,65:415-419.
    [19] American Diabetes Association. Glycemic Targets:Standards of Medical Care in Diabetesd 2018[J]. Diabetes Care, 2018,41:S55-S64.
    [20] Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management ALGORITHM-2017 Executive Summary[J].Endocr Pract, 2017,23:207-238.
    [21] Araki E, Haneda M, Kasuga M et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society[J].J Diabetes Investig,2017,8:123-125.
    [22] Lu JY, Ma XJ, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes[J].Diabetes Care,2018,41:2370-2376.
    [23] 戴冬君,陆静毅,张磊,等.应用葡萄糖在目标范围内时间评价2型糖尿病血糖控制情况的适宜切点分析[J].中华医学杂志, 2020,100:2990-2996.
    [24] Lu J, Wang C, Shen Y, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes:A Prospective Cohort Study[J].Diabetes Care, 2021, 44:549-555.
    [25] Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation:recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42:1593-1603.
    [26] 中国老年保健医学研究会老年内分泌与代谢病分会,中国毒理学会临床毒理专业委员会.老年人多重用药安全管理专家共识[J].中国全科医学, 2018,21:3533-3544.
    [27] Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years[J]. Clin Ther, 2012,34:2082-2090.
    [28] Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease:Results from the EMPA-REG OUTCOME® trial[J]. J Diabetes Investig,2019,10:760-770.
    [29] Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes:an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol[J]. 2019,7:606-617.
    [30] Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type 2 diabetes mellitus worldwide:Baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract[J]. 2019,151:20-32.
    [31] Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes:updated systematic review and meta-analysis[J]. Lancet,2016,387:435-443.
    [32] 高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识[J].中华内科杂志,2017,56:235-248.
    [33] 中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志, 2020,36:1-13.
    [34] Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes:an emerging challenge[J]. Osteoporos Int,2018,29:2585-2596.
    [35] 吴芸杨,陈晓宏,季晶俊,等.肌肉衰减综合征的诊断和治疗进展[J].医学综述,2020,26:4499-4503.
    [36] Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease[J]. Ageing Res Rev,2019,54:100936.
    [37] Lee AA, Piette JD, Heisler M, et al. Diabetes self-management and glycemic control:The role of autonomy support from informal health supporters[J]. Health Psychol,2019,38:122-132.
    [38] Lee AA, Heisler M, Trivedi R, et al. Autonomy support from informal health supporters:links with selfcare activities, healthcare engagement, metabolic outcomes, and cardiac risk among Veterans with type 2 diabetes[J]. J Behav Med, 2021,44:241-252.
    [39] Koetsenruijter J, Eikelenboom Nv, Lieshout Jv, et al. Social support and self-management capabilities in diabetes patients:An international observational study[J]. Patient Educ Couns,2016,99:638-643.
  • 加载中
计量
  • 文章访问数:  13
  • HTML全文浏览量:  2
  • PDF下载量:  14
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-09
  • 网络出版日期:  2022-06-11

目录

    /

    返回文章
    返回